摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2'-Amino-3'-cyano-6'-[2-cyclopropylmethoxy-6-(4-methoxy-benzyloxy)-phenyl]-3,4,5,6-tetrahydro-2H-[4,4']bipyridinyl-1-carboxylic acid tert-butyl ester | 406213-57-8

中文名称
——
中文别名
——
英文名称
2'-Amino-3'-cyano-6'-[2-cyclopropylmethoxy-6-(4-methoxy-benzyloxy)-phenyl]-3,4,5,6-tetrahydro-2H-[4,4']bipyridinyl-1-carboxylic acid tert-butyl ester
英文别名
Tert-butyl 4-[2-amino-3-cyano-6-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]pyridin-4-yl]piperidine-1-carboxylate
2'-Amino-3'-cyano-6'-[2-cyclopropylmethoxy-6-(4-methoxy-benzyloxy)-phenyl]-3,4,5,6-tetrahydro-2H-[4,4']bipyridinyl-1-carboxylic acid tert-butyl ester化学式
CAS
406213-57-8
化学式
C34H40N4O5
mdl
——
分子量
584.715
InChiKey
MJALQPCUZXQHKS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6
  • 重原子数:
    43
  • 可旋转键数:
    11
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    120
  • 氢给体数:
    1
  • 氢受体数:
    8

反应信息

  • 作为反应物:
    描述:
    2'-Amino-3'-cyano-6'-[2-cyclopropylmethoxy-6-(4-methoxy-benzyloxy)-phenyl]-3,4,5,6-tetrahydro-2H-[4,4']bipyridinyl-1-carboxylic acid tert-butyl ester盐酸 作用下, 以 1,4-二氧六环 为溶剂, 反应 10.0h, 生成 2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-yl nicotinonitrile
    参考文献:
    名称:
    Synthesis and structure–activity relationships of novel IKK-β inhibitors. Part 3: Orally active anti-inflammatory agents
    摘要:
    A series of 2-amino-3-cyano-4-alkyl-6-(2-hydroxyphenyl)pyridine derivatives was synthesized and evaluated as IkappaB kinase beta (IKK-beta) inhibitors. Modification of a novel IKK-beta inhibitor 1 (IKK-beta IC50 = 1500 nM, Cell IC50 = 8000 nM) at the 4-phenyl ring and 6-phenol group on the pyridine core ring resulted in a marked increased in biological activities. An optimized compound, 2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-yl nicotinonitrile, exhibited excellent in vitro profiles (IKK-beta IC50 = 8.5 nM, Cell IC50 = 60 nM) and a strong oral efficacy in in vivo anti-inflammatory assays (significant effects at 1 mg/kg, po in arachidonic acid-induced ear edema model in mice). (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.05.041
  • 作为产物:
    参考文献:
    名称:
    Synthesis and structure–activity relationships of novel IKK-β inhibitors. Part 3: Orally active anti-inflammatory agents
    摘要:
    A series of 2-amino-3-cyano-4-alkyl-6-(2-hydroxyphenyl)pyridine derivatives was synthesized and evaluated as IkappaB kinase beta (IKK-beta) inhibitors. Modification of a novel IKK-beta inhibitor 1 (IKK-beta IC50 = 1500 nM, Cell IC50 = 8000 nM) at the 4-phenyl ring and 6-phenol group on the pyridine core ring resulted in a marked increased in biological activities. An optimized compound, 2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-yl nicotinonitrile, exhibited excellent in vitro profiles (IKK-beta IC50 = 8.5 nM, Cell IC50 = 60 nM) and a strong oral efficacy in in vivo anti-inflammatory assays (significant effects at 1 mg/kg, po in arachidonic acid-induced ear edema model in mice). (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.05.041
点击查看最新优质反应信息

文献信息

  • [EN] PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK- beta ) INHIBITING ACTIVITY<br/>[FR] DERIVES DE PYRIDINE AVEC ACTIVITE INHIBITRICE DE L'IKB-KINASE (IKK-KINASE9
    申请人:BAYER AG
    公开号:WO2002024679A1
    公开(公告)日:2002-03-28
    Pyridine compounds of general formula (I) wherein -R1 represents, or in which R11 is hydrogen, C¿1-6? alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di (C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or -O-(CH2)n-R?111 ; R2¿ represents hydrogen or halogen; R3 represents hydrogen, -CR?31R32R33¿, or -NR?34R35; R4¿ is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C¿1-6? alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.
    通式为(I)的吡啶化合物,其中-R1代表,或其中R11为氢,C1-6烷基,卤素,羟基,C1-12烷氧基,硝基,氨基,C1-6烷基磺酰胺基,C1-6烷氧羰基,C1-6烷基氨基,二(C1-6烷基)氨基,C1-6烷酰胺基,苯基C1-6烷基氨基,苯基磺酰胺基,或-O-(CH2)n-R?111; R2代表氢或卤素; R3代表氢,-CR?31R32R33¿,或-NR?34R35; R4为氢,氨甲酰基,氰基,羧基等; R5为氨基,C1-6烷基氨基,二C1-6烷基氨基等或其盐。该化合物具有优异的抗炎活性和其他生物活性。
  • Pyridine derivatives
    申请人:Murata Toshiki
    公开号:US20060100246A1
    公开(公告)日:2006-05-11
    This invention is to provide a process for producing 2-amino-4,6-disubstituted nicotinic acid ester analogs and salts thereof, comprising the reaction shown by the following scheme. The ester analogs can be prepared in one pot, and in good yield by using tertiary alkyl cyanoacetate. Furthermore, the method is useful for preparing derivatives of various analogs of the ester, e.g. alkyl substituted and aryl substituted analogs.
    这项发明提供了一种制备2-氨基-4,6-二取代烟酸酯类似物及其盐的方法,包括以下方案所示的反应。使用三级烷基氰乙酸酯可以在一个反应釜中高产率地制备酯类似物。此外,该方法还可用于制备各种酯类似物的衍生物,例如烷基取代和芳基取代的类似物。
  • PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY
    申请人:Bayer HealthCare AG
    公开号:EP1326856B1
    公开(公告)日:2007-12-19
  • US6562811B1
    申请人:——
    公开号:US6562811B1
    公开(公告)日:2003-05-13
  • US6984649B1
    申请人:——
    公开号:US6984649B1
    公开(公告)日:2006-01-10
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-